Combining Two Venom Peptides Into One Creates a Better Pain Channel Blocker
Enzymatically ligating a pore-blocking cone snail peptide with a gating-modifier spider peptide creates a bivalent NaV1.7 inhibitor with enhanced potency for pain treatment.
Quick Facts
What This Study Found
Enzymatic ligation of two venom peptides targeting different NaV1.7 binding sites creates a bivalent inhibitor with enhanced sodium channel blockade.
Key Numbers
9-AA optimal linker; improved affinity/potency vs PaurTx3 or KIIIA alone; sortase A ligation
How They Did This
Evolved sortase A-mediated enzymatic ligation, electrophysiology for NaV1.7 inhibition measurement, structural characterization of double-knotted peptides.
Why This Research Matters
NaV1.7 is a genetically validated pain target, but single-site inhibitors haven't achieved sufficient clinical efficacy. Bivalent inhibitors hitting two sites simultaneously could finally unlock this target.
The Bigger Picture
This bivalent approach could be applied to other ion channel targets, creating more potent and selective peptide therapeutics by simultaneously engaging multiple binding sites.
What This Study Doesn't Tell Us
In vitro electrophysiology data only. In vivo pain relief not demonstrated. Manufacturing complexity of double-knotted peptides may limit clinical development.
Questions This Raises
- ?Does bivalent NaV1.7 inhibition produce better pain relief in animal models?
- ?Can the double-knotted peptide be produced at scale?
- ?Does simultaneous dual-site binding improve NaV1.7 selectivity over other sodium channels?
Trust & Context
- Key Stat:
- Bivalent First double-knotted peptide combining two venom toxins to simultaneously block two NaV1.7 binding sites
- Evidence Grade:
- In vitro proof-of-concept with electrophysiology data. Innovative approach at early discovery stage.
- Study Age:
- Published in 2020. NaV1.7-targeted pain therapeutics remain an active area of drug development.
- Original Title:
- Enzymatic Ligation of a Pore Blocker Toxin and a Gating Modifier Toxin: Creating Double-Knotted Peptides with Improved Sodium Channel NaV1.7 Inhibition.
- Published In:
- Bioconjugate chemistry, 31(1), 64-73 (2020)
- Authors:
- Tran, Hue N T, Tran, Poanna, Deuis, Jennifer R(3), Agwa, Akello J, Zhang, Alan H, Vetter, Irina, Schroeder, Christina I
- Database ID:
- RPEP-05171
Evidence Hierarchy
Frequently Asked Questions
Why is NaV1.7 important for pain?
People born without functional NaV1.7 channels feel no pain, proving this sodium channel is essential for pain signaling. However, drugs targeting just one site on NaV1.7 haven't been effective enough clinically, motivating the dual-site approach.
How were two venom peptides combined?
Using an enzyme called evolved sortase A, researchers chemically linked a spider toxin (which targets NaV1.7's voltage sensor) to a cone snail toxin (which blocks the channel pore). The resulting double-knotted peptide can engage both sites simultaneously for stronger inhibition.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-05171APA
Tran, Hue N T; Tran, Poanna; Deuis, Jennifer R; Agwa, Akello J; Zhang, Alan H; Vetter, Irina; Schroeder, Christina I. (2020). Enzymatic Ligation of a Pore Blocker Toxin and a Gating Modifier Toxin: Creating Double-Knotted Peptides with Improved Sodium Channel NaV1.7 Inhibition.. Bioconjugate chemistry, 31(1), 64-73. https://doi.org/10.1021/acs.bioconjchem.9b00744
MLA
Tran, Hue N T, et al. "Enzymatic Ligation of a Pore Blocker Toxin and a Gating Modifier Toxin: Creating Double-Knotted Peptides with Improved Sodium Channel NaV1.7 Inhibition.." Bioconjugate chemistry, 2020. https://doi.org/10.1021/acs.bioconjchem.9b00744
RethinkPeptides
RethinkPeptides Research Database. "Enzymatic Ligation of a Pore Blocker Toxin and a Gating Modi..." RPEP-05171. Retrieved from https://rethinkpeptides.com/research/tran-2020-enzymatic-ligation-of-a
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.